Inventor · disambiguated record
Lino Valdez
Also filed as: VALDEZ LINO · VALDEZ LINO J
15 granted patents·7 pending applications·11 citations·filing 2010–2024
88Inventor score
Files withVERTEX PHARMA7LIGAND PHARM INC5DART NEUROSCIENCE CAYMAN LTD4DART NEUROSCIENCE LLC3ZHI LIN2
Top patents by PatentIndex Score
22 records- 0178US11365191B2Substituted cyclohexyl compounds as NOP inhibiiorsDART NEUROSCIENCE LLC·Filed 2019·Granted Jun 21, 2022·2 cites·25 claims
- 0277US2025092024A1Substituted cyclohexyl compounds as nop inhibitorsDART NEUROSCIENCE LLC·Filed 2024·Application pending·0 cites
- 0376US9150572B2Substituted naphthyridine and quinoline compounds as MAO inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Granted Oct 6, 2015·2 cites·3 claims
- 0476US9102674B2Substituted naphthyridine and quinoline compounds as MAO inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Granted Aug 11, 2015·2 cites·35 claims
- 0574US11945808B2Substituted cyclohexyl compounds as NOP inhibitorsDART NEUROSCIENCE LLC·Filed 2022·Granted Apr 2, 2024·0 cites·20 claims
- 0674US2025179091A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 0773US9144557B2Hematopoietic growth factor mimetic small molecule compounds and their usesZHI LIN·Filed 2010·Granted Sep 29, 2015·3 cites·21 claims
- 0872US9675605B2Substituted naphthyridine and quinoline compounds as MAO inhibitorsDART NEUROSCIENCE (CAYMAN) LTD·Filed 2015·Granted Jun 13, 2017·1 cites·7 claims
- 0970US11413274B2Methods and compositions associated with the granulocyte colony-stimulating factor receptorLIGAND PHARM INC·Filed 2020·Granted Aug 16, 2022·0 cites·8 claims
- 1067US9622991B2Hematopoietic growth factor mimetic small molecule compounds and their usesLIGAND PHARM INC·Filed 2015·Granted Apr 18, 2017·1 cites·23 claims
- 1166US10736875B2Methods and compositions associated with the granulocyte colony-stimulating factor receptorLIGAND PHARM INC·Filed 2018·Granted Aug 11, 2020·0 cites·16 claims
- 1264US12269831B2Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Granted Apr 8, 2025·0 cites·41 claims
- 1361US2025122218A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2023·Application pending·0 cites
- 1459US9956213B2Substituted naphthyridine and quinoline compounds as MAO inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2017·Granted May 1, 2018·0 cites·18 claims
- 1558US2025034110A1Lpar1 antagonists and uses thereofPIPELINE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1656US12324802B2Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Granted Jun 10, 2025·0 cites·53 claims
- 1756US2023382925A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 1856US2024018161A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 1956US2024150377A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2055US9492430B2Methods and compositions associated with the granulocyte colony-stimulating factor receptorLIGAND PHARM INC·Filed 2012·Granted Nov 15, 2016·0 cites·12 claims
- 2153US10111859B2Methods and compositions associated with the granulocyte colony-stimulating factor receptorLIGAND PHARM INC·Filed 2016·Granted Oct 30, 2018·0 cites·8 claims
- 2229US8680150B2Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptorsZHI LIN·Filed 2010·Granted Mar 25, 2014·0 cites·13 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →